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The Effect of Solar-Simulated Radiation on the Elicitation Phase
of Contact Hypersensitivity does not Differ Between Controls
and Patients with Polymorphic Light Eruption
Roy A. Palmer, John L. M. Hawk, Anthony R. Young, and Sue L. Walker
Photobiology Unit, St John’s Institute of Dermatology, Division of Skin Sciences, King’s College London, London, UK
It has been suggested that polymorphic light eruption (PLE) is characterized by a failure of ultraviolet radiation
(UVR)-induced immunosuppression, resulting in a type-IV hypersensitivity response to photoinduced antigens. We
measured the effect of solar-simulated radiation (SSR) on the elicitation phase of contact hypersensitivity to 2,4-
dinitrochlorobenzene (DNCB), in ten PLE patients and 11 controls. Subjects were given a sensitizing dose of DNCB,
and 3 wk later were exposed to 0.75 and 2 minimum erythema doses (MED) of SSR on the upper inner arm.
Immediately and 24 h later these sites, and a non-irradiated control site, were challenged with DNCB. The resulting
increase in skin thickness was measured with high-frequency ultrasound. Overall, 2 MED caused 17%–20% sup-
pression of elicitation responses (compared with 93% suppression of sensitization reported previously), but the
effect of SSR varied greatly between subjects, with some subjects showing potentiated responses, which may be of
relevance to false-positive reactions in photopatch testing. In a repeated measures general linear model, SSR
overall caused significant suppression of responses (po0.001); there was less suppression in older subjects
(p¼ 0.009) but there was no significant difference between PLE patients and age-matched normal controls. These
results contrast with our previous ﬁnding of a resistance to UVR-induced suppression of sensitization to DNCB in
PLE. This difference may reﬂect the greater importance of Langerhans cells in the sensitization phase, and is
consistent with the hypothesis that PLE arises from impaired suppression of Langerhans cell activation or
migration.
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In 1942, Epstein suggested that polymorphic light eruption
(PLE) might be due to a type-IV hypersensitivity response to
autologous antigens generated by ultraviolet radiation (UVR)
(Epstein, 1942). We have previously shown that PLE pa-
tients are resistant to UVR-induced suppression of the
sensitization phase of contact hypersensitivity (CHS) to
2,4-dinitrochlorobenzene (DNCB) compared with controls
(Palmer and Friedmann, 2004; van de Pas et al, 2004). This
lack of immunosuppression may permit T cell sensitization
to UVR-induced antigens. In this study, we have investigat-
ed whether the pathogenesis of PLE may involve a second
step, namely a similar failure of UVR to suppress the elici-
tation phase, thus encouraging a type-IV hypersensitivity
reaction to develop.
The majority of severely affected patients in the United
Kingdom experience the rash each year on the first day of
exposure to strong sunshine (Palmer et al, 2004). We there-
fore studied the effect of a single exposure of solar-simu-
lated radiation (SSR) on the elicitation phase of CHS among
PLE patients and non-photosensitive controls. We quanti-
fied CHS responses immediately after SSR exposure in
DNCB-sensitized subjects. In addition, to explore the time
course of the effects of SSR we also studied its effect on
elicitation responses when the application of DNCB was
delayed by 24 h.
Results
As expected, the single exposures of relatively small areas
to SSR did not induce PLE in any of the 21 subjects. The
gender, sun-reactive skin type, median minimum erythema
dose (MED), and other characteristics of the two groups are
shown in Table I. Considering the groups combined, Table II
shows baseline skin thickness and the increase in thickness
that occurred with ethanol (negative control), UVR, and
DNCB.
Application of ethanol to unirradiated skin resulted in a
small but significant increase in skin thickness (7%,
p¼0.02; visit V). Exposure to 2 MED alone increased skin
thickness by 24% (po0.001) at 72 h post-UVR. The in-
creases in skin thickness due to UVR and ethanol were
controlled for by subtracting the increase in thickness due
to ethanol within each site (0, 0.75, and 2 MED) from the
increase in thickness due to DNCB within the same site.
This allowed a more accurate quantification of CHS.
Abbreviations: CHS, contact hypersensitivity; DNCB, 2,4 din-
itrochlorobenzene; MED, minimum erythema dose; PAR, primary
allergic response; PLE, polymorphic light eruption; PUVA, psor-
alen-UVA; SSR, solar-simulated radiation; UVR, ultraviolet radiation
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Considering the increase in skin thickness due to DNCB,
there was a high correlation between results on visit V and
visit VI (DNCB with 2 MED; correlation coefficient 0.94,
po0.001). The effect of SSR on DNCB reactions varied
greatly between subjects, with some subjects (both normal
controls and PLE patients) showing enhanced CHS re-
sponses compared with unirradiated sites (Fig 1). Overall,
0.75 and 2 MED caused approximately 3% and 20% sup-
pression, respectively, of CHS elicitation responses (visit V,
Table II). In the repeated measures model, SSR caused
significant suppression of DNCB responses (po0.001); the
quadratic component of trend was significant (p¼0.01), in-
dicating that the relationship between SSR dose and its
effect on DNCB reactions was not linear. The following did
not have an impact on the effect of SSR on DNCB reactions:
a diagnosis of PLE, the elicitation dose of DNCB, the time of
application of DNCB, and the patient’s MED. With increas-
ing age, however, there was less suppression of DNCB re-
actions by SSR (p¼ 0.009, Fig 2). Sensitization to DNCB (as
measured by the diameter of the primary allergic response
(PAR)) was not associated with age (correlation coefficient
0.08, p¼0.74).
Considering the clinical assessment of reactions on a
scale of 0–5, of the 126 DNCB reaction sites (six sites in
each of 21 volunteers), 113 had a clinical score of 3 or 4 (i.e.,
they were erythematous and palpable without blistering), so
that clinical assessment using this scale was an insensitive
method of assessing the effect of SSR.
Discussion
We found that 2 MED of SSR (without DNCB) caused a
mean increase in skin thickness of 24% 72 h later (Table II).
We chose a priori to calculate the immunosuppressive ef-
fect of SSR by subtracting the thickness of irradiated con-
trol skin from the DNCBþSSR reaction. If we had chosen to
subtract the thickness of normal (non-irradiated) skin, we
might not have detected any immunosuppression. There-
fore, our results indicate that 2 MED of SSR caused at most
20% suppression, and possibly less. It is also conceivable
that the SSR was having some systemic effect, suppressing
the elicitation reactions at the non-irradiated site, but this
problem has not been found to exist in another model of the
expression phase of CHS (Damian et al, 1999). We meas-
ured skin thickness rather than erythema to assess the
strength of DNCB reactions because 2 MED is an er-
ythemogenic dose, and because we have previously found
it to be a more reliable method of quantifying reactions lo-
cated on the upper inner arm (Kelly et al, 1998).
UVR has been shown to suppress both the sensitization
and elicitation phases of CHS. These two phases are
Table I. Characteristics of the two groups
Controls PLE patients
Number of subjects 11 10
Mean age (y) 33 38
Percentage male 18 10
Percentage atopica 27 40
Number of subjects with Fitzpatrick skin type
I 1 1
II 6 6
III 3 1
IV 1 2
MED (mJ per cm2)
Median 400 450
Range 260–630 320–780
Diameter of primary allergic response (mm)
Median 11.0 11.8
Range 0–19 0–20.5
Number of subjects receiving each elicitation dose of DNCB (mg)
0.78 1 2
1.56 2 1
3.12 3 2
6.25 0 1
12.5 5 4
PLESI scores NA Median¼ 69, range¼ 25–87.5
NA, not applicable; PLE, polymorphic light eruption; DNCB, 2,4
dinitrochlorobenzene; PLESI, Polymorphic Light Eruption Severity Index.
aAtopy was defined as a personal history of asthma, hayfever, or atopic
eczema.
Table II. Mean skin thickness (millimetres  100) in all 21
subjects
Site
Visit V skin
thickness
(mean  SD)
Visit VI skin
thickness
(mean  SD)
1 Unirradiated skin 80  15 83  13
2 Unirradiated
skinþethanol
86  17 87  17
3 Unirradiated
skinþDNCB
162  37 170  40
4 0.75 MED 81  12 82  13
5 0.75 MEDþ ethanol 87  12 85  17
6 0.75 MEDþDNCB 161  43 163  33
7 2 MED 99  19 88  18
8 2 MEDþ ethanol 102  17 94  18
9 2 MEDþDNCB 163  52 163  52
Effect of 0.75 MED
on increase in
thickness caused
by DNCBa
3% suppression
SD¼  34%
6% suppression
SD¼  32%
Effect of 2 MED on
increase in thickness
caused by DNCBb
20% suppression
SD¼  47%
17% suppression
SD¼  47%
DNCB and ethanol had been administered 72 h previously. The read-
ings for visit V represent the effect of applying ethanol and DNCB im-
mediately after SSR; those for visit VI represent the effect of applying
ethanol and DNCB 24 h after SSR.
DNCB, 2,4-dinitrochlorobenzene; MED, minimum erythema dose; SSR,
solar-simulated radiation.
a(Site 65)(site 3site 2)/(site 3site 2).
b(Site 98)(site 3site 2)/(site 3site 2).
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immunologically distinct. Antigen presentation during the
sensitization phase is mediated by epidermal Langerhans
cells and dermal dendritic cells and stimulation of naı¨ve T
cells takes place in the draining lymph nodes. Successful
antigen presentation requires migration of dendritic cells
from the skin to the draining lymph nodes and expression of
several co-stimulatory signals in order to stimulate T cell
proliferation and clonal expansion successfully. In the elici-
tation phase, antigen-reactive/memory T cells can be stim-
ulated by any cell expressing major histocompatibility
complex class II and therefore antigen presentation can take
place at the challenge site by several different cell types in-
cluding macrophages, mast cells, and keratinocytes and is
therefore less dependent on Langerhans cells (reviewed by
Schwarz, 2003).
To date, little has been done to compare directly the ef-
fect of UVR on the sensitization and elicitation responses in
the same CHS model. A course of psoralen-UVA (PUVA)
treatment given for psoriasis caused substantially greater
suppression of the sensitization phase of DNCB than of the
elicitation phase (Moss et al, 1982). Previously, no human
studies have directly compared the effects of one exposure
of UVR on sensitization and elicitation responses in the
same CHS model. We found that 2 MED had a small effect
on the elicitation phase (17%–20% suppression), compared
with 93% suppression of the sensitization phase that we
have previously reported in the same model (Kelly et al,
2000). The level of suppression observed in this study is
within the range of that previously reported in humans in a
model using elicitation responses to nickel; one exposure of
SSR equivalent to approximately 0.6 MED suppressed CHS
to nickel by about 20% (p¼0.04, Damian et al, 1999). In
that study, maximal suppression (of 34%) was observed
after 4 daily exposures to 0.6 MED.
We found no significant difference in suppression of the
elicitation phase in PLE versus controls, although it is pos-
sible that the low levels of immunosuppression have made it
more difficult to determine a difference that exists between
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Figure 1
The increase in skin thickness (millimeters  100) due to 2,4-din-
itrochlorobenzene (DNCB) on visit V. DNCB had been administered
immediately after solar-simulated radiation (SSR), 72 h previously.
These values are after subtraction of increase in thickness occurring
due to ethanol and SSR. In (a) and (b) each line represents one subject;
(c) is a boxplot representing all subjects showing maximum, median,
and minimum values, interquartile ranges, and two outlying values.
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Figure2
The relationship between age and the effect of solar-simulated
radiation (SSR) on 2,4-dinitrochlorobenzene (DNCB) reactions. The
total effect of SSR is calculated by summing the effect of SSR at all four
sites tested (0.75 and 2 minimum erythema doses on visits V and VI).
Negative values represent suppression and positive values represent
potentiation of DNCB reactions by SSR.
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the two groups. This is unlikely, however, as both groups
showed a wide variation in the effect of SSR on elicitation
responses, with some subjects having reactions potentiated
by SSR (Fig 1). This phenomenon has been reported pre-
viously. Tie et al (1995) sensitized subjects through non-
irradiated skin, and administered UVB to another site for 4
consecutive days. Eleven days later subjects were chal-
lenged with antigen and seven of 12 healthy subjects
showed enhanced responses at the irradiated site com-
pared with a non-irradiated site. Enhancement of the elici-
tation phase by UVR has also been reported in mice (Polla
et al, 1986; Yoshikawa et al, 1992; Grabbe et al, 1995), and
is occasionally seen in photopatch testing. In the latter,
suspected antigens are applied to the skin, 24–48 h later
5–10 J per cm2 of UVA is given, and after another 48 h the
skin is inspected for reactions (British Photodermatology
Group, 1997). If photopotentiation of contact allergic reac-
tions occurs, it has to be differentiated from true photoal-
lergy. Although the protocol is different, our results as well
as those of Tie et al indicate that enhancement of elicitation
responses may be a frequent event.
Our study was also sensitive enough to observe a sig-
nificant resistance of the elicitation phase to UVR-induced
immunosuppression with increasing age (p¼0.009), de-
spite most patients being within the relatively narrow range
of 21–47 y old. This effect is likely to be due to the effect of
chronological aging rather than photoaging because this
study was conducted on the relatively photoprotected skin
of the upper inner arms. The ability of the skin immune
system to adapt to environmental stress is known to decline
with chronological age (reviewed by Sunderkotter et al,
1997). Age has little effect on sensitization to contact aller-
gens except at extremes of old age (in which sensitization is
reduced) (Friedmann, 1994), and we did not detect an as-
sociation between age and strength of sensitization as
measured by the PAR.
PLE is often regarded as a type-IV hypersensitivity re-
action to ultraviolet-induced cutaneous antigen(s), and it
has been shown that PLE epidermal cells can stimulate
autologous peripheral blood mononuclear cell proliferation
after exposure to UVR (Gonzalez-Amaro et al, 1991). It has
also been reported that UVR-induced depletion of epider-
mal Langerhans cells is impaired in PLE (Kolgen et al, 1999),
although other investigators have not confirmed this (Black-
burn,1 Wackernagel et al, 2004). These results contrast with
our previous finding of a resistance to the effect of UVR on
the sensitization phase of CHS in PLE patients (Palmer and
Friedmann, 2004; van de Pas et al, 2004). This difference
may reflect the greater importance of Langerhans cells in
the sensitization phase, and is consistent with the hypoth-
esis that PLE arises from impaired suppression of La-
ngerhans cell activation or migration.
Materials and Methods
The study was approved by the Local Research Ethics Committee
and adhered to the Declaration of Helsinki guidelines, and partic-
ipants gave written informed consent. Twenty-seven subjects were
recruited; two PLE patients were excluded because they devel-
oped PLE and solar urticaria, respectively, from irradiation given
during the study, and four subjects were excluded because they
failed to sensitize to DNCB. Therefore, results were obtained on 11
patients with PLE and 10 healthy controls between the ages of 20
and 74 y. The diagnosis of PLE was made on clinical grounds. The
morphology of the PLE eruption was predominantly papular in ten
patients and papulovesicular in one patient. All the patients had
experienced episodes of PLE in England during the preceding 12
mo, and the severity of their condition was scored using the Pol-
ymorphic Light Eruption Severity Index (Palmer et al, 2004). Vol-
unteers were excluded from the study if they were receiving
medication likely to affect immune function or sensitivity to UVR,
had a history of exposure to DNCB or a history of skin cancer, or
were pregnant or lactating. The study was conducted between
February 2003 and April 2004; there was no association between
group and date of sensitization. An outline of the protocol is shown
in Fig 3.
Sensitization to DNCB (visit I) 31.25 mg DNCB (Sigma-Aldrich,
Dorset, UK) in 50 mL of ethanol (0.0625% DNCB) was applied to the
right buttock on a paper disc 12 mm in diameter in a Finn chamber
(Epitest, Tuusula, Finland). Subjects were instructed to remove this
after 48 h.
Measurement of the PAR and establishing the MED (visit
II) Three weeks after sensitization, the diameter of the PAR that
developed on the sensitization site was measured in two axes and
averaged. SSR was generated by a 1 kW xenon arc solar simulator
(Oriel, Leatherhead, UK), whose characteristics have been de-
scribed previously (‘‘Filter 2’’ in Harrison and Young, 2002). Irradi-
ance was routinely determined with 1400 A radiometer (Inter-
national Light, Newbury Port, Massachusetts) with a UVB detector
(SEL240 photodiode and solar blind filter SPS300), calibrated
against a DM150 double-monochromator spectroradiometer
Visit I; Apply DNCB 
3 weeks 
Visit II; Test MED 
24 hours 
Visit III; Assess MED. 
Give doses of SSR corresponding to 0, 0.75, 2 MED
 Apply DNCB “A”
24 hours 
Visit IV; Apply DNCB “B”
24 hours 
 (Remove DNCB A) 
24 hours 
Visit V; Assess reactions to “A”
(Remove DNCB “B”) 
24 hours 
Visit VI; Assess reactions to “B”
Figure3
Outline of protocol.
1Blackburn A, Ling TC, Brownrigg M, Rhodes LE, Gibbs NK:
UVB-induced Langerhans cell trafficking in polymorphic light erup-
tion. Br J Dermatol 150:804, 2004 (abstr).
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(Bentham Instruments, Reading, UK). The MED was determined at
the top of the inner aspect of the right upper arm with eight doses
of SSR ranging from 160 to 1230 mJ per cm2 (UVB component of
SSR), increasing in approximately 25% increments, given to areas
each measuring 1 cm2.
UVR exposure and application of DNCB (visit III) Twenty four
hours later, the dose of SSR that caused just perceptible erythema
was defined as the MED. Two areas each measuring 8 cm  4 cm
on the left upper inner arm were exposed to 0.75 MED and 2 MED
of SSR; these areas were separated by approximately 4 cm. DNCB
was applied in 20 mL absolute ethanol in an 8 mm Finn chamber on
the medial side of both areas, and on an unirradiated area on the
right upper inner arm (inferior to the MED series). The DNCB dose
was chosen from a set of possible doses (0.78, 1.56, 3.12, 6.25,
12.5 mg) according to the size and morphology of the PAR, patients
with a strong PAR receiving a low dose. Because ethanol can be an
irritant, a control chamber containing only ethanol was also applied
at each site. The Finn chambers were left in place for 48 h.
Application of DNCB (visit IV) Twenty four hours later, the same
dose of DNCB was applied lateral to the DNCB applied on the
previous visit, within the 0.75 MED, 2 MED, and unirradiated sites.
Control chambers containing ethanol were also applied at each
site and left in place for 48 h.
Assessment of elicitation reactions to DNCB (visit V) Forty-
eight hours later, at the sites used on visit III (DNCB and ethanol in
areas irradiated with 0, 0.75, and 2 MED), skin thickness was as-
sessed using high-frequency ultrasound (Quality Medical Instru-
ments, Silchester, Reading, UK) as previously described (Kelly
et al, 1998). Five measurements were taken at each site and the
mean was calculated. In addition, skin thickness was assessed with-
in each irradiated area at a site where a Finn chamber had not been
applied. A clinical assessment of reactions was made at all sites
using a scale from 0 to 5 as previously described (Kelly et al, 1998).
Assessment of elicitation reactions to DNCB (visit VI) Twenty
four hours later, the procedure used in visit V was repeated, at the
sites used in visit IV.
Statistical analysis Within each site (0, 0.75, and 2 MED), the
strength of a DNCB reaction was calculated by subtracting the
increase in thickness with ethanol from the increase in thickness
with DNCB. Among all subjects, skin thickness after ethanol, 0.75
MED, and 2 MED were compared with baseline thickness using a
paired samples t test. Bivariate correlations were calculated with
Pearson’s correlation coefficient. The effect of SSR on reactions to
DNCB in PLE patients and controls was considered in a repeated
measures general linear model with two within-subjects factors,
namely dose of SSR (0, 0.75, or 2 MED) and time of application of
DNCB (0 or 24 h after SSR), one between-subjects factor (pres-
ence/absence of PLE), with age, dose of DNCB, and the patients’
MED as covariates. All p values were two-tailed and significance
was assumed at the 5% level.
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